Impact of the new FIGO 2013 classification on prognosis of stage I epithelial ovarian cancers.

16 The retrospective analysis of the ICON3 trial for early-stage ovarian cancer showed a trend toward improved PFS in favor of the combination of carboplatin/paclitaxel instead of carboplatin alone, but no difference in OS. 22 The GOG 157 study compared 3 vs 6 cycles of carboplatin/paclitaxel and no difference was shown in RFS or OS between the regimens, although increased toxicity occurred with 6 cycles. 23 In our study, we have accurate data on chemotherapy available for each individual case, based on an interdisciplinary tumor board decision in accordance with the international guidelines.

also in 53,322 other papers